Insider Selling: Haemonetics Co. (NYSE:HAE) EVP Sells 2,305 Shares of Stock

Haemonetics Co. (NYSE:HAE) EVP Anila Lingamneni sold 2,305 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the transaction, the executive vice president now owns 12,295 shares of the company’s stock, valued at $1,168,025. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Haemonetics Stock Performance

HAE traded down $1.95 during trading on Wednesday, reaching $93.25. 911,085 shares of the company’s stock were exchanged, compared to its average volume of 458,956. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The business has a 50 day moving average price of $83.59 and a 200 day moving average price of $82.81. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $97.13. The company has a market capitalization of $4.74 billion, a P/E ratio of 37.91, a PEG ratio of 2.23 and a beta of 0.34.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. The business had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.85 earnings per share. As a group, analysts predict that Haemonetics Co. will post 3.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on HAE shares. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Finally, Barrington Research reiterated an “outperform” rating and set a $105.00 price target on shares of Haemonetics in a report on Friday, April 12th.

Institutional Trading of Haemonetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Haemonetics by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after acquiring an additional 25,451 shares during the period. Wellington Management Group LLP increased its stake in Haemonetics by 3.2% in the fourth quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier’s stock valued at $279,454,000 after acquiring an additional 101,029 shares during the period. Dimensional Fund Advisors LP increased its stake in Haemonetics by 7.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 826,731 shares of the medical instruments supplier’s stock valued at $70,697,000 after acquiring an additional 59,670 shares during the period. Westfield Capital Management Co. LP boosted its position in Haemonetics by 27.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock valued at $60,888,000 after buying an additional 152,098 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Haemonetics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 534,694 shares of the medical instruments supplier’s stock valued at $45,722,000 after buying an additional 8,901 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.